Possible Therapeutics for Pseudomyxoma Peritonei: A Rare, Lethal, and the Least Investigated Disease

Abstract Pseudomyxoma peritonei (PMP) refers to a growth disorder characterized by glycoprotein neoplasm in the peritoneum, where mucin oversecretion occurs. The tumors of appendix region are well associated with PMP; however, ovarian, colon, stomach, pancreas, and urachus have also been linked PMP. Other mucinous pelvis, paracolic gutters, greater omentum, retrohepatic space, Treitz ligament can be reason for Despite being rare having slow rate, PMP lethal without treatment. It is treated neoadjuvant chemotherapy option cytoreductive surgery intraperitoneal chemotherapy. In current study, we hypothesize that there may novel gentle ways inhibit or eliminate mucin. Dr. David Morris has used mucolytics—such as bromelain N-acetyl cysteine solubilize present review, aimed study regulation expression promoter methylation, drugs mucin, such boldine, amiloride, naltrexone, dexamethasone, retinoid acid receptors antagonist. This review explored some possible pathways, inhibition Na + , Ca2+ channels induction DNA methyltransferase along ten-eleven translocation enzymes, which good targets control Mucins strong adhesive molecules play great roles clinging cells cell cell. Besides, they greatly involved metastasis act disease markers cancers. Diagnostic exclusive initiation progression. Therefore, explores various target diseases, specifically